期刊文献+

黏菌素联用不同药物对老年患者多药耐药鲍氏不动杆菌体外联合药敏研究 被引量:4

In vitro drug susceptibility testing for colistin combined with different antibiotics against multidrug-resistant Acinetobacter baumannii strains isolated from elderly patients
原文传递
导出
摘要 目的对老年患者多耐药和泛耐药鲍氏不动杆菌进行体外联合药敏试验,为临床治疗提供可靠的理论依据。方法采用琼脂稀释法对2012年1月-2013年12月114株多药耐药鲍氏不动杆菌进行体外联合药敏试验,联合方案共3种:头孢哌酮/舒巴坦(SCF)+多黏菌素E(PE)、多黏菌素E+美罗培南(MEM)、米诺环素(MH)+多黏菌素E,计算抑菌浓度(FIC)指数判断联用效果。结果 SCF和PE联合,94.7%表现为协同或相加,以相加为主;PE和MEM联合,99.1%表现为协同或相加,其中约40.0%为协同;PE和MH联合,99.1%表现为协同或相加,以协同作用为主,所有组合均无拮抗作用。结论 PE与SCF、MEM、MH体外联合应用效果显著,联用能有效降低单药最低抑菌浓度(MIC)值。 OBJECTIVE To conduct the in vitro drug susceptibility testing of multidrug-resistant and pandrug-resistant Acinetobacter baumannii strains isolated from elderly patients so as to provide reliable theoretical basis for clinical treatment.METHODS The in vitro combined drug susceptibility testing was performed for 114 strains of multidrug-resistant A.baumannii strains isolated from Jan 2012 to Dec 2013 by using agar dilution method.The three combinations included the cefoperazone-sulbactam(SCF)plus polymyxin E(PE),PE plus meropenem(MEM),and minocycline(MH)plus PE.The FIC indices were calculated to judge the combination effects.RESULTS When PE was combined with SCF,94.7% of the isolates displayed synergism or addition effect,the major effect was addition.When PE was combined with MEM,99.1% of the isolates displayed synergism or addition effect,about40.0% of which were synergism.When PE was combined with MH,99.1% of the isolates displayed synergism or addition effect,the major effect was synergism.There was no antagonism in all of combinations.CONCLUSIONPE combined with SCF,MEM,or MH can achieve remarkable effect,and the drug combinations can effectively reduce the MIC of single drug.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第17期3863-3865,共3页 Chinese Journal of Nosocomiology
基金 全军医学科技"十二五"科研项目重点基金资助项目(BWS11-C073)
关键词 鲍氏不动杆菌 老年患者 多药耐药 联合药敏 Acinetobacter baumannii Elderly patient Multidrug-resistant Combined drug susceptibility testing
  • 相关文献

参考文献7

  • 1Zhang H,Zhang XJ,Xu YC,et al.CHINET 2012surveillance of antibiotic resistance in Acinetobacter baumannii isolates in China[J].Chin J Infect Chemothe,2014(14):392-397.
  • 2Maragakis LL,Perl TM.Acinetobacter baumannii:epidemiology,antimicrobial resistance,and treatment options[J].Clin Infect Dis,2008,46(8):1254-1263.
  • 3Higgins PG,Wisplinghoff H,Stefanik D,et al.In vitro activities of the beta-lactamase inhibitors clavulanic acid,sulbactam,and tazobactam alone or in combination with betalactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains[J].Antimicrob Agents Chemother,2004,48(5):1586-1592.
  • 4Falagas ME,Kasiakou SK.Colistin:the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections[J].Clin Infect Dis,2005,40(9):1333-1341.
  • 5Linden PK,Paterson DL.Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia[J].Clin Infect Dis,2006,43(Suppl 2):S89-94.
  • 6Michalopoulos A,Fotakis D,Virtzili S,et al.Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria:aprospective study[J].Respir Med,2008,102(3):407-412.
  • 7Gordon NC,Wareham DW.A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline[J].J Antimicrob Chemother,2009,63(4):775-780.

同被引文献37

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部